;PMID: 11258969
;source_file_2655.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..40] = [t:0..40]
;1)sentence:[e:46..232] = [t:46..232]
;2)section:[e:236..297] = [t:236..297]
;3)section:[e:301..462] = [t:301..462]
;4)sentence:[e:466..918] = [t:466..918]
;5)sentence:[e:919..1113] = [t:919..1113]
;6)sentence:[e:1114..1245] = [t:1114..1245]
;7)sentence:[e:1246..1471] = [t:1246..1471]
;8)sentence:[e:1472..1619] = [t:1472..1619]
;9)sentence:[e:1620..1759] = [t:1620..1759]
;10)sentence:[e:1760..2019] = [t:1760..2019]
;11)sentence:[e:2020..2250] = [t:2020..2250]
;12)sentence:[e:2251..2392] = [t:2251..2392]
;13)sentence:[e:2393..2614] = [t:2393..2614]
;14)section:[e:2618..2663] = [t:2618..2663]

;section 0 Span:0..40
;Chem Res Toxicol. 2001 Feb;14(2):202-10.
(SEC
  (FRAG (NNP:[0..4] Chem) (NNP:[5..8] Res) (NNP:[9..16] Toxicol) (.:[16..17] .)
        (CD:[18..22] 2001) (CC:[23..30] Feb;14-LRB-) (CD:[30..31] 2)
        (-RRB-:[31..32] -RRB-) (::[32..33] :) (CD:[33..36] 202)
        (HYPH:[36..37] -) (CD:[37..39] 10) (.:[39..40] .)))

;sentence 1 Span:46..232
;Oxidations of N(omega)-hydroxyarginine analogues and various
;N-hydroxyguanidines  by NO synthase II: key role of tetrahydrobiopterin in
;the reaction mechanism and  substrate selectivity.
;[60..94]:substance:"N(omega)-hydroxyarginine analogues"
;[85..94]:substance:"analogues"
;[107..126]:substance:"N-hydroxyguanidines"
;[131..145]:substance:"NO synthase II"
;[159..178]:substance:"tetrahydrobiopterin"
;[210..219]:substance:"substrate"
(SENT
  (NP-HLN
    (NP
      (NP (NNS:[46..56] Oxidations))
      (PP (IN:[57..59] of)
        (NP
          (NP (NN:[60..84] N-LRB-omega-RRB--hydroxyarginine)
              (NNS:[85..94] analogues))
          (CC:[95..98] and)
          (NP (JJ:[99..106] various) (NNS:[107..126] N-hydroxyguanidines))))
      (PP (IN:[128..130] by)
        (NP (NN:[131..133] NO) (NN:[134..142] synthase) (CD:[143..145] II))))
    (::[145..146] :)
    (NP
      (NP (JJ:[147..150] key) (NN:[151..155] role))
      (PP (IN:[156..158] of)
        (NP (NN:[159..178] tetrahydrobiopterin)))
      (PP-LOC (IN:[179..181] in)
        (NP (DT:[182..185] the)
          (NML
            (NML (NN:[186..194] reaction) (NN:[195..204] mechanism))
            (CC:[205..208] and)
            (NML (NN:[210..219] substrate) (NN:[220..231] selectivity))))))
    (.:[231..232] .)))

;section 2 Span:236..297
;Moali C, Boucher JL, Renodon-Corniere A, Stuehr DJ, Mansuy D.
(SEC
  (FRAG (NNP:[236..241] Moali) (NNP:[242..243] C) (,:[243..244] ,)
        (NNP:[245..252] Boucher) (NNP:[253..255] JL) (,:[255..256] ,)
        (NNP:[257..264] Renodon) (HYPH:[264..265] -) (NNP:[265..273] Corniere)
        (NNP:[274..275] A) (,:[275..276] ,) (NNP:[277..283] Stuehr)
        (NNP:[284..286] DJ) (,:[286..287] ,) (NNP:[288..294] Mansuy)
        (NNP:[295..297] D.)))

;section 3 Span:301..462
;Laboratoire de Chimie et Biochimie Pharmacologiques et Toxicologiques, UMR
;8601  CNRS, Universite Paris V, 45 Rue des Saints-Peres, 75270 Paris Cedex
;06, France.
(SEC
  (FRAG (NNP:[301..312] Laboratoire) (IN:[313..315] de) (NNP:[316..322] Chimie)
        (NNP:[323..325] et) (NNP:[326..335] Biochimie)
        (NNP:[336..352] Pharmacologiques) (NNP:[353..355] et)
        (NNP:[356..370] Toxicologiques) (,:[370..371] ,) (NNP:[372..375] UMR)
        (CD:[376..380] 8601) (NNP:[382..386] CNRS) (,:[386..387] ,)
        (IN:[388..398] Universite) (NNP:[399..404] Paris) (NNP:[405..406] V)
        (,:[406..407] ,) (CD:[408..410] 45) (NNP:[411..414] Rue)
        (NNP:[415..418] des) (NNP:[419..425] Saints) (HYPH:[425..426] -)
        (NNP:[426..431] Peres) (,:[431..432] ,) (CD:[433..438] 75270)
        (NNP:[439..444] Paris) (NNP:[445..450] Cedex) (CD:[451..453] 06)
        (,:[453..454] ,) (NNP:[455..461] France) (.:[461..462] .)))

;sentence 4 Span:466..918
;Oxidations of L-arginine 2, homo-L-arginine 1, their N(omega)-hydroxy 
;derivatives 4 and 3 (NOHA and homo-NOHA, respectively), and four 
;N-hydroxyguanidines, N(omega)-hydroxynor-L-arginine 5 (nor-NOHA), 
;N(omega)-hydroxydinor-L-arginine 6 (dinor-NOHA), 
;N-(4-chlorophenyl)-N'-hydroxyguanidine (8), and N-hydroxyguanidine (7)
;itself,  by either NOS II or (6R)-5,6,7,8-tetrahydro-L-biopterin (BH4)-free
;NOS II, have  been studied in a comparative manner.
;[480..492]:substance:"L-arginine 2"
;[494..511]:substance:"homo-L-arginine 1"
;[519..550]:substance:"N(omega)-hydroxy  derivatives 4"
;[519..548]...[555..556]:substance:"N(omega)-hydroxy  derivatives"..."3"
;[558..562]:substance:"NOHA"
;[567..576]:substance:"homo-NOHA"
;[597..622]:substance:"four  N-hydroxyguanidines"
;[624..656]:substance:"N(omega)-hydroxynor-L-arginine 5"
;[658..666]:substance:"nor-NOHA"
;[670..704]:substance:"N(omega)-hydroxydinor-L-arginine 6"
;[706..716]:substance:"dinor-NOHA"
;[720..762]:substance:"N-(4-chlorophenyl)-N'-hydroxyguanidine (8)"
;[768..790]:substance:"N-hydroxyguanidine (7)"
;[810..816]:substance:"NOS II"
;[820..855]:substance:"(6R)-5,6,7,8-tetrahydro-L-biopterin"
;[856..873]:substance:"(BH4)-free NOS II"
(SENT
  (S
    (NP-SBJ-2
      (NP (NNS:[466..476] Oxidations))
      (PP (IN:[477..479] of)
        (NP
          (NP (NN:[480..490] L-arginine) (CD:[491..492] 2))
          (,:[492..493] ,)
          (NP (NN:[494..509] homo-L-arginine) (CD:[510..511] 1))
          (,:[511..512] ,)
          (NP
            (NP (PRP$:[513..518] their)
              (NML
                (NML
                  (NML-1 (NN:[519..535] N-LRB-omega-RRB--hydroxy)
                         (NNS:[537..548] derivatives))
                  (CD:[549..550] 4))
                (CC:[551..554] and)
                (NML
                  (NML-1 (-NONE-:[554..554] *P*))
                  (CD:[555..556] 3))))
            (PRN (-LRB-:[557..558] -LRB-)
              (NP
                (NP (NN:[558..562] NOHA) (CC:[563..566] and)
                    (NN:[567..576] homo-NOHA))
                (,:[576..577] ,)
                (ADVP (RB:[578..590] respectively)))
              (-RRB-:[590..591] -RRB-)))
          (,:[591..592] ,) (CC:[593..596] and)
          (NP
            (NP (CD:[597..601] four) (NNS:[603..622] N-hydroxyguanidines))
            (,:[622..623] ,)
            (NP
              (NP
                (NP (NN:[624..654] N-LRB-omega-RRB--hydroxynor-L-arginine)
                    (CD:[655..656] 5))
                (NP (-LRB-:[657..658] -LRB-) (NN:[658..666] nor-NOHA)
                    (-RRB-:[666..667] -RRB-)))
              (,:[667..668] ,)
              (NP
                (NP (NN:[670..702] N-LRB-omega-RRB--hydroxydinor-L-arginine)
                    (CD:[703..704] 6))
                (NP (-LRB-:[705..706] -LRB-) (NN:[706..716] dinor-NOHA)
                    (-RRB-:[716..717] -RRB-)))
              (,:[717..718] ,)
              (NP (NN:[720..758] N--LRB-4-chlorophenyl-RRB--N'-hydroxyguanidine)
                  (-LRB-:[759..760] -LRB-) (CD:[760..761] 8)
                  (-RRB-:[761..762] -RRB-))
              (,:[762..763] ,) (CC:[764..767] and)
              (NP
                (NP (NN:[768..786] N-hydroxyguanidine) (-LRB-:[787..788] -LRB-)
                    (CD:[788..789] 7) (-RRB-:[789..790] -RRB-))
                (NP (PRP:[791..797] itself)))))))
      (,:[797..798] ,)
      (PP (IN:[800..802] by)
        (NP (CC:[803..809] either)
          (NP (NN:[810..813] NOS) (CD:[814..816] II))
          (CC:[817..819] or)
          (NP
            (ADJP
              (NML
                (NML (NN:[820..855] -LRB-6R-RRB--5,6,7,8-tetrahydro-L-biopterin))
                (NML (-LRB-:[856..857] -LRB-) (NN:[857..860] BH4)
                     (-RRB-:[860..861] -RRB-)))
              (HYPH:[861..862] -) (JJ:[862..866] free))
            (NN:[867..870] NOS) (CD:[871..873] II)))))
    (,:[873..874] ,)
    (VP (VBP:[875..879] have)
      (VP (VBN:[881..885] been)
        (VP (VBN:[886..893] studied)
          (NP-2 (-NONE-:[893..893] *))
          (PP-MNR (IN:[894..896] in)
            (NP (DT:[897..898] a) (JJ:[899..910] comparative)
                (NN:[911..917] manner))))))
    (.:[917..918] .)))

;sentence 5 Span:919..1113
;Recombinant BH4-free NOS II catalyzes the  oxidation of all
;N-hydroxyguanidines by NADPH and O2, with formation of NO2(-)  and NO3(-) at
;rates between 20 and 80 nmol min(-1) (mg of protein)(-1).
;[931..946]:substance:"BH4-free NOS II"
;[979..998]:substance:"N-hydroxyguanidines"
;[1002..1007]:substance:"NADPH"
;[1012..1014]:substance:"O2"
;[1034..1040]:substance:"NO2(-)"
;[1046..1052]:substance:"NO3(-)"
;[1070..1072]:quantitative-value:"20"
;[1077..1079]:quantitative-value:"80"
;[1080..1112]:quantitative-units:"nmol min(-1) (mg of protein)(-1)"
(SENT
  (S
    (NP-SBJ (JJ:[919..930] Recombinant)
      
      (ADJP (NN:[931..934] BH4) (HYPH:[934..935] -) (JJ:[935..939] free))
      (NN:[940..943] NOS) (CD:[944..946] II))
    (VP (VBZ:[947..956] catalyzes)
      (NP
        (NP
          (NP (DT:[957..960] the) (NN:[962..971] oxidation))
          (PP (IN:[972..974] of)
            (NP (DT:[975..978] all) (NNS:[979..998] N-hydroxyguanidines))))
        (PP (IN:[999..1001] by)
          (NP (NN:[1002..1007] NADPH) (CC:[1008..1011] and) (NN:[1012..1014] O2))))
      (,:[1014..1015] ,)
      (PP (IN:[1016..1020] with)
        (NP
          (NP (NN:[1021..1030] formation))
          (PP (IN:[1031..1033] of)
            (NP
              (NP (NN:[1034..1037] NO2) (-LRB-:[1037..1038] -LRB-)
                  (SYM:[1038..1039] -) (-RRB-:[1039..1040] -RRB-))
              (CC:[1042..1045] and)
              (NP (NN:[1046..1049] NO3) (-LRB-:[1049..1050] -LRB-)
                  (SYM:[1050..1051] -) (-RRB-:[1051..1052] -RRB-))))
          (PP-MNR (IN:[1053..1055] at)
            (NP
              (NP (NNS:[1056..1061] rates))
              (PP (IN:[1062..1069] between)
                (NP
                  (NP
                    (NML (CD:[1070..1072] 20)
                      (NML-1 (-NONE-:[1072..1072] *P*)))
                    (NML-2 (-NONE-:[1072..1072] *P*)))
                  (CC:[1073..1076] and)
                  (NP
                    (NML (CD:[1077..1079] 80)
                      (NML-1 (NN:[1080..1084] nmol)))
                    (NML-2 (NN:[1085..1092] min-LRB--1-RRB-)))
                  (NP (-LRB-:[1093..1094] -LRB-)
                    (NML
                      (NML (NN:[1094..1096] mg))
                      (PP (IN:[1097..1099] of)
                        (NP (NN:[1100..1107] protein))))
                    (-RRB-:[1107..1108] -RRB-) (-LRB-:[1108..1109] -LRB-)
                     (SYM:[1109..1110] -) (CD:[1110..1111] 1)
                     (-RRB-:[1111..1112] -RRB-)))))))))
    (.:[1112..1113] .)))

;sentence 6 Span:1114..1245
;In the  case of compound 8, formation of the corresponding urea and cyanamide
;was also  detected besides that of NO2(-) and NO3(-).
;[1130..1140]:substance:"compound 8"
;[1173..1177]:substance:"urea"
;[1182..1191]:substance:"cyanamide"
;[1227..1233]:substance:"NO2(-)"
;[1238..1244]:substance:"NO3(-)"
(SENT
  (S
    (PP (IN:[1114..1116] In)
      (NP
        (NP (DT:[1117..1120] the) (NN:[1122..1126] case))
        (PP (IN:[1127..1129] of)
          (NP (NN:[1130..1138] compound) (CD:[1139..1140] 8)))))
    (,:[1140..1141] ,)
    (NP-SBJ-2
      (NP (NN:[1142..1151] formation))
      (PP (IN:[1152..1154] of)
        (NP (DT:[1155..1158] the)
          (NML
            (NML
              (ADJP-1 (VBG:[1159..1172] corresponding))
              (NN:[1173..1177] urea))
            (CC:[1178..1181] and)
            (NML
              (ADJP-1 (-NONE-:[1181..1181] *P*))
              (NN:[1182..1191] cyanamide))))))
    (VP (VBD:[1192..1195] was)
      (ADVP (RB:[1196..1200] also))
      (VP (VBN:[1202..1210] detected)
        (NP-2 (-NONE-:[1210..1210] *))
        (PP (IN:[1211..1218] besides)
          (NP
            (NP (DT:[1219..1223] that))
            (PP (IN:[1224..1226] of)
              (NP
                (NP (NN:[1227..1230] NO2) (-LRB-:[1230..1231] -LRB-)
                    (SYM:[1231..1232] -) (-RRB-:[1232..1233] -RRB-))
                (CC:[1234..1237] and)
                (NP (NN:[1238..1241] NO3) (-LRB-:[1241..1242] -LRB-)
                    (SYM:[1242..1243] -) (-RRB-:[1243..1244] -RRB-))))))))
    (.:[1244..1245] .)))

;sentence 7 Span:1246..1471
;These BH4-free NOS II-dependent  reactions are inhibited by modulators of
;electron transfer in NOS such as  thiocitrulline (TC) or imidazole (ImH), but
;not by Arg, and are completely  suppressed by superoxide dismutase (SOD).
;[1252..1267]:substance:"BH4-free NOS II"
;[1306..1316]:substance:"modulators"
;[1341..1344]:substance:"NOS"
;[1354..1368]:substance:"thiocitrulline"
;[1370..1372]:substance:"TC"
;[1377..1386]:substance:"imidazole"
;[1388..1391]:substance:"ImH"
;[1405..1408]:substance:"Arg"
;[1444..1464]:substance:"superoxide dismutase"
;[1466..1469]:substance:"SOD"
(SENT
  (S
    (NP-SBJ-3 (DT:[1246..1251] These)
      (ADJP (NN:[1252..1255] BH4) (HYPH:[1255..1256] -) (JJ:[1256..1260] free))
      (ADJP
        (NML (NN:[1261..1264] NOS) (CD:[1265..1267] II))
        (HYPH:[1267..1268] -) (JJ:[1268..1277] dependent))
      (NNS:[1279..1288] reactions))
    (VP
      (VP (VBP:[1289..1292] are)
        (VP
          (VP (VBN:[1293..1302] inhibited)
            (NP-3 (-NONE-:[1302..1302] *))
            (PP=2 (IN:[1303..1305] by)
              (NP-LGS
                (NP (NNS:[1306..1316] modulators))
                (PP (IN:[1317..1319] of)
                  (NP
                    (NP (NN:[1320..1328] electron) (NN:[1329..1337] transfer))
                    (PP (IN:[1338..1340] in)
                      (NP (NN:[1341..1344] NOS)))))
                (PP (JJ:[1345..1349] such) (IN:[1350..1352] as)
                  (NP
                    (NP
                      (NP (NN:[1354..1368] thiocitrulline))
                      (NP (-LRB-:[1369..1370] -LRB-) (NN:[1370..1372] TC)
                          (-RRB-:[1372..1373] -RRB-)))
                    (CC:[1374..1376] or)
                    (NP
                      (NP (NN:[1377..1386] imidazole))
                      (NP (-LRB-:[1387..1388] -LRB-) (NN:[1388..1391] ImH)
                          (-RRB-:[1391..1392] -RRB-))))))))
          (,:[1392..1393] ,) (CC:[1394..1397] but)
          (VP (RB:[1398..1401] not)
            (PP=2 (IN:[1402..1404] by)
              (NP-LGS (NN:[1405..1408] Arg))))))
      (,:[1408..1409] ,) (CC:[1410..1413] and)
      (VP (VBP:[1414..1417] are)
        (ADVP-EXT (RB:[1418..1428] completely))
        (VP (VBN:[1430..1440] suppressed)
          (NP-3 (-NONE-:[1440..1440] *))
          (PP (IN:[1441..1443] by)
            (NP-LGS
              (NP (NN:[1444..1454] superoxide) (NN:[1455..1464] dismutase))
              (NP (-LRB-:[1465..1466] -LRB-) (NN:[1466..1469] SOD)
                  (-RRB-:[1469..1470] -RRB-)))))))
    (.:[1470..1471] .)))

;sentence 8 Span:1472..1619
;They exhibit characteristics very  similar to those previously reported for
;microsomal cytochrome P450-catalyzed  oxidation of N-hydroxyguanidines.
;[1559..1574]:cyp450:"cytochrome P450"
;[1599..1618]:substance:"N-hydroxyguanidines"
(SENT
  (S
    (NP-SBJ (PRP:[1472..1476] They))
    (VP (VBP:[1477..1484] exhibit)
      (NP
        (NP (NNS:[1485..1500] characteristics))
        (ADJP (RB:[1501..1505] very) (JJ:[1507..1514] similar)
          (PP (TO:[1515..1517] to)
            (NP
              (NP-1 (DT:[1518..1523] those))
              (VP
                (ADVP-TMP (RB:[1524..1534] previously))
                (VBN:[1535..1543] reported)
                (NP-1 (-NONE-:[1543..1543] *))
                (PP (IN:[1544..1547] for)
                  (NP
                    (NP (JJ:[1548..1558] microsomal)
                      (ADJP
                        (NML (NN:[1559..1569] cytochrome) (NN:[1570..1574] P450))
                        (HYPH:[1574..1575] -) (VBN:[1575..1584] catalyzed))
                      (NN:[1586..1595] oxidation))
                    (PP (IN:[1596..1598] of)
                      (NP (NNS:[1599..1618] N-hydroxyguanidines)))))))))))
    (.:[1618..1619] .)))

;sentence 9 Span:1620..1759
;Both P450 and BH4-free NOS II reactions appear  to be mainly performed by
;O2(.-) derived from the oxidase function of those heme  proteins.
;[1625..1629]:cyp450:"P450"
;[1634..1649]:substance:"BH4-free NOS II"
;[1694..1700]:substance:"O2(.-)"
;[1718..1725]:substance:"oxidase"
;[1744..1758]:substance:"heme  proteins"
(SENT
  (S
    (NP-SBJ-3 (CC:[1620..1624] Both)
      (NML
        (NML (NN:[1625..1629] P450)
          (NML-2 (-NONE-:[1629..1629] *P*)))
        (CC:[1630..1633] and)
        (NML
          (NML
            (ADJP (NN:[1634..1637] BH4) (HYPH:[1637..1638] -)
                  (JJ:[1638..1642] free))
            (NN:[1643..1646] NOS) (CD:[1647..1649] II))
          (NML-2 (NNS:[1650..1659] reactions)))))
    (VP (VBP:[1660..1666] appear)
      (S
        (NP-SBJ (-NONE-:[1666..1666] *))
        (VP (TO:[1668..1670] to)
          (VP (VB:[1671..1673] be)
            (ADVP (RB:[1674..1680] mainly))
            (VP (VBN:[1681..1690] performed)
              (NP-3 (-NONE-:[1690..1690] *))
              (PP (IN:[1691..1693] by)
                (NP-LGS
                  (NP-1 (NN:[1694..1696] O2) (-LRB-:[1696..1697] -LRB-)
                        (SYM:[1697..1698] .) (SYM:[1698..1699] -)
                        (-RRB-:[1699..1700] -RRB-))
                  (VP (VBN:[1701..1708] derived)
                    (NP-1 (-NONE-:[1708..1708] *))
                    (PP (IN:[1709..1713] from)
                      (NP
                        (NP (DT:[1714..1717] the) (NN:[1718..1725] oxidase)
                            (NN:[1726..1734] function))
                        (PP (IN:[1735..1737] of)
                          (NP (DT:[1738..1743] those)
                             (NN:[1744..1748] heme) (NNS:[1750..1758] proteins)))))))))))))
    (.:[1758..1759] .)))

;sentence 10 Span:1760..2019
;In the presence of increasing concentrations of BH4, these  nonselective
;oxidations progressively disappear while a much more selective 
;monooxygenation takes place only with the N-hydroxyguanidines that are 
;recognized well by NOS II, NOHA, homo-NOHA, and 8.
;[1808..1811]:substance:"BH4"
;[1939..1958]:substance:"N-hydroxyguanidines"
;[1988..1994]:substance:"NOS II"
;[1996..2000]:substance:"NOHA"
;[2002..2011]:substance:"homo-NOHA"
;[2017..2018]:substance:"8"
(SENT
  (S
    (PP (IN:[1760..1762] In)
      (NP
        (NP (DT:[1763..1766] the) (NN:[1767..1775] presence))
        (PP (IN:[1776..1778] of)
          (NP
            (NP (VBG:[1779..1789] increasing) (NNS:[1790..1804] concentrations))
            (PP (IN:[1805..1807] of)
              (NP (NN:[1808..1811] BH4)))))))
    (,:[1811..1812] ,)
    (NP-SBJ (DT:[1813..1818] these) (JJ:[1820..1832] nonselective)
            (NNS:[1833..1843] oxidations))
    (ADVP-MNR (RB:[1844..1857] progressively))
    (VP (VBP:[1858..1867] disappear)
      (SBAR-ADV (IN:[1868..1873] while)
        (S
          (NP-SBJ (DT:[1874..1875] a)
            (ADJP
              (ADVP (RB:[1876..1880] much) (RBR:[1881..1885] more))
              (JJ:[1886..1895] selective))
            (NN:[1897..1912] monooxygenation))
          (VP (VBZ:[1913..1918] takes)
            (NP (NN:[1919..1924] place))
            (PP-MNR
              (ADVP (RB:[1925..1929] only))
              (IN:[1930..1934] with)
              (NP
                (NP (DT:[1935..1938] the) (NNS:[1939..1958] N-hydroxyguanidines))
                (SBAR
                  (WHNP-1 (WDT:[1959..1963] that))
                  (S
                    (NP-SBJ-1 (-NONE-:[1963..1963] *T*))
                    (VP (VBP:[1964..1967] are)
                      (VP (VBN:[1969..1979] recognized)
                        (NP-1 (-NONE-:[1979..1979] *))
                        (ADVP (RB:[1980..1984] well))
                        (PP (IN:[1985..1987] by)
                          (NP-LGS
                            (NP (NN:[1988..1991] NOS) (CD:[1992..1994] II))
                            (,:[1994..1995] ,)
                            (NP (NN:[1996..2000] NOHA))
                            (,:[2000..2001] ,)
                            (NP (NN:[2002..2011] homo-NOHA))
                            (,:[2011..2012] ,) (CC:[2013..2016] and)
                            (NP (CD:[2017..2018] 8))))))))))))))
    (.:[2018..2019] .)))

;sentence 11 Span:2020..2250
;These monooxygenations are  much more chemoselective (8 being selectively
;transformed into the corresponding  urea and NO) and are inhibited by Arg but
;not by SOD, as expected for reactions  performed by the NOS Fe(II)-O2
;species.
;[2074..2075]:substance:"8"
;[2130..2134]:substance:"urea"
;[2139..2141]:substance:"NO"
;[2164..2167]:substance:"Arg"
;[2179..2182]:substance:"SOD"
;[2228..2241]:substance:"NOS Fe(II)-O2"
(SENT
  (S
    (NP-SBJ-5 (DT:[2020..2025] These) (NNS:[2026..2042] monooxygenations))
    (VP
      (VP (VBP:[2043..2046] are)
        (ADJP-PRD
          (ADJP (RB:[2048..2052] much) (RBR:[2053..2057] more))
          (JJ:[2058..2072] chemoselective))
        (PRN (-LRB-:[2073..2074] -LRB-)
          (S
            (NP-4 (CD:[2074..2075] 8))
            (VP (VBG:[2076..2081] being)
              (ADVP (RB:[2082..2093] selectively))
              (VP (VBN:[2094..2105] transformed)
                (NP-4 (-NONE-:[2105..2105] *))
                (PP (IN:[2106..2110] into)
                  (NP
                    (NP (DT:[2111..2114] the) (VBG:[2115..2128] corresponding)
                        (NN:[2130..2134] urea))
                    (CC:[2135..2138] and)
                    (NP (NN:[2139..2141] NO)))))))
          (-RRB-:[2141..2142] -RRB-)))
      (CC:[2143..2146] and)
      (VP (VBP:[2147..2150] are)
        (VP
          (VP (VBN:[2151..2160] inhibited)
            (NP-5 (-NONE-:[2160..2160] *))
            (PP=3 (IN:[2161..2163] by)
              (NP-LGS (NN:[2164..2167] Arg))))
          (CC:[2168..2171] but)
          (VP (RB:[2172..2175] not)
            (PP=3 (IN:[2176..2178] by)
              (NP-LGS (NN:[2179..2182] SOD)))))
        (,:[2182..2183] ,)
        (PP (IN:[2184..2186] as)
          (ADJP (VBN:[2187..2195] expected)
            (PP (IN:[2196..2199] for)
              (NP
                (NP-1 (NNS:[2200..2209] reactions))
                (VP (VBN:[2211..2220] performed)
                  (NP-1 (-NONE-:[2220..2220] *))
                  (PP (IN:[2221..2223] by)
                    (NP-LGS (DT:[2224..2227] the)
                       (NN:[2228..2231] NOS)
                      (NML (NN:[2232..2238] Fe-LRB-II-RRB-)
                           (HYPH:[2238..2239] -) (NN:[2239..2241] O2))
                      (NN:[2242..2249] species))))))))))
    (.:[2249..2250] .)))

;sentence 12 Span:2251..2392
;Altogether, these results provide a  further clear illustration of the key
;role of BH4 in regulating the  monooxygenase/oxidase ratio in NOS.
;[2334..2337]:substance:"BH4"
;[2357..2370]:substance:"monooxygenase"
;[2371..2378]:substance:"oxidase"
;[2388..2391]:substance:"NOS"
(SENT
  (S
    (ADVP (RB:[2251..2261] Altogether))
    (,:[2261..2262] ,)
    (NP-SBJ (DT:[2263..2268] these) (NNS:[2269..2276] results))
    (VP (VBP:[2277..2284] provide)
      (NP
        (NP (DT:[2285..2286] a) (JJ:[2288..2295] further)
            (JJ:[2296..2301] clear) (NN:[2302..2314] illustration))
        (PP (IN:[2315..2317] of)
          (NP
            (NP (DT:[2318..2321] the) (JJ:[2322..2325] key)
                (NN:[2326..2330] role))
            (PP (IN:[2331..2333] of)
              (NP (NN:[2334..2337] BH4)))
            (PP (IN:[2338..2340] in)
              (S-NOM
                (NP-SBJ (-NONE-:[2340..2340] *))
                (VP (VBG:[2341..2351] regulating)
                  (NP (DT:[2352..2355] the)
                    (NML (NN:[2357..2370] monooxygenase) (SYM:[2370..2371] /)
                         (NN:[2371..2378] oxidase))
                    (NN:[2379..2384] ratio))
                  (PP-LOC (IN:[2385..2387] in)
                    (NP (NN:[2388..2391] NOS))))))))))
    (.:[2391..2392] .)))

;sentence 13 Span:2393..2614
;They also suggest a possible implication of  NOSs in the oxidative metabolism
;of certain classes of xenobiotics such as  N-hydroxyguanidines, not only via
;their monooxygenase function but also via  their oxidase function.
;[2438..2442]:substance:"NOSs"
;[2493..2504]:substance:"xenobiotics"
;[2514..2533]:substance:"N-hydroxyguanidines"
;[2554..2567]:substance:"monooxygenase"
;[2597..2604]:substance:"oxidase"
(SENT
  (S
    (NP-SBJ (PRP:[2393..2397] They))
    (ADVP (RB:[2398..2402] also))
    (VP (VBP:[2403..2410] suggest)
      (NP
        (NP (DT:[2411..2412] a) (JJ:[2413..2421] possible)
            (NN:[2422..2433] implication))
        (PP (IN:[2434..2436] of)
          (NP (NNS:[2438..2442] NOSs))))
      (PP-LOC (IN:[2443..2445] in)
        (NP
          (NP (DT:[2446..2449] the) (JJ:[2450..2459] oxidative)
              (NN:[2460..2470] metabolism))
          (PP (IN:[2471..2473] of)
            (NP
              (NP (JJ:[2474..2481] certain) (NNS:[2482..2489] classes))
              (PP (IN:[2490..2492] of)
                (NP (NNS:[2493..2504] xenobiotics)))
              (PP (JJ:[2505..2509] such) (IN:[2510..2512] as)
                (NP (NNS:[2514..2533] N-hydroxyguanidines)))))))
      (,:[2533..2534] ,)
      (PP-MNR
        (PP
          (ADVP (RB:[2535..2538] not) (RB:[2539..2543] only))
          (IN:[2544..2547] via)
          (NP (PRP$:[2548..2553] their) (NN:[2554..2567] monooxygenase)
              (NN:[2568..2576] function)))
        (CC:[2577..2580] but)
        (PP
          (ADVP (RB:[2581..2585] also))
          (IN:[2586..2589] via)
          (NP (PRP$:[2591..2596] their) (NN:[2597..2604] oxidase)
              (NN:[2605..2613] function)))))
    (.:[2613..2614] .)))

;section 14 Span:2618..2663
;PMID: 11258969 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2618..2622] PMID) (::[2622..2623] :) (CD:[2624..2632] 11258969)
        (NN:[2633..2634] -LSB-) (NNP:[2634..2640] PubMed) (::[2641..2642] -)
        (NN:[2643..2650] indexed) (IN:[2651..2654] for)
        (NNP:[2655..2663] MEDLINE-RSB-)))
